Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 706 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2025-12-29 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It specifies the trading window closure period related to the upcoming quarterly financial results announcement for the quarter ending 31st December 2025. The document does not contain any financial data, results, or detailed report but is an announcement related to insider trading compliance and timing of trading restrictions. It is short (1949 characters) and serves as a regulatory notification rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2025-12-26 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is an intimation letter addressed to stock exchanges (NSE and BSE) regarding the allotment of equity shares under an employee stock option scheme (ESOS 2012). It details the number of shares allotted, the increase in paid-up capital, and disclosures as per SEBI regulations. The document includes a statement as per SEBI regulations about the share allotment. There are no financial statements or comprehensive financial data, nor is this a report or earnings release. It is an announcement of a capital change due to share allotment under an employee stock option scheme. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is 5563 characters, which is sufficient for a detailed announcement, not just a brief notice. Hence, the classification is SHA with high confidence.
2025-12-12 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains multiple sections including a letter to stock exchanges about the publication of un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. It references Regulation 47 of SEBI Listing Regulations and mentions that the full financial results and auditor's limited review report are available on the company's website and stock exchange websites. The document also includes detailed unaudited financial results tables and notes indicating that these results were reviewed by the audit committee and approved by the board. Additionally, there is a notice about the extension of a rights issue closing date, which is a capital raising activity. The document is lengthy (15,000 characters) and contains actual financial data and analysis for the quarter and half year, not just an announcement or a link to a report. Therefore, the primary content is a comprehensive interim/quarterly financial report with substantive financial data and analysis. The rights issue notice is a secondary element but does not override the main classification. Hence, the document should be classified as an Interim / Quarterly Report (IR).
2025-11-14 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled as an "Investor Presentation" and explicitly states it is prepared for information purposes related to the business overview and financial results of Themis Medicare Limited. It includes detailed consolidated financial highlights for Q2 and H1 FY26, management comments, balance sheet data, and strategic business information. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis. It is not a brief announcement or a certification letter, nor is it a full annual report or audit report. The content and format align with a detailed presentation aimed at investors, focusing on financials, strategy, and market position. Therefore, the appropriate classification is Investor Presentation (IP).
2025-11-13 English
Outcome of Board Meeting
Regulatory Filings
2025-11-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.